• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3: Howard William Carson claimed ownership of 10,000 units of Common Stock

    3/11/21 1:16:24 PM ET
    $PAIC
    Business Services
    Finance
    Get the next $PAIC alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Carson William Howard

    (Last) (First) (Middle)
    2703 COTTONWOOD LANE

    (Street)
    COLLEYVILLE TX 76034

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    03/11/2021
    3. Issuer Name and Ticker or Trading Symbol
    Petra Acquisition Inc. [ PAIC ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock 10,000(1) D
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Mr. Carson will receive ten thousand (10,000)shares of the Company's common stock from the Company's Sponsor, Petra Investment Holdings, LLC, as compensation for his service on the Board. The shares have yet to be transferred.
    William Howard Carson 03/11/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PAIC alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $PAIC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PAIC
    SEC Filings

    See more
    • Petra Acquisition, Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Unregistered Sales of Equity Securities, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Change in Shell Company Status

      8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

      1/14/22 4:28:56 PM ET
      $PAIC
      Business Services
      Finance
    • Petra Acquisition, Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

      1/13/22 3:53:16 PM ET
      $PAIC
      Business Services
      Finance
    • Petra Acquisition, Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

      1/12/22 4:49:37 PM ET
      $PAIC
      Business Services
      Finance

    $PAIC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Revelation Biosciences Inc. Receives Approval to Initiate Phase 2b Viral Challenge Study of REVTx 99, an Experimental Prophylactic Treatment for the Prevention of Respiratory Viral Infections

      - Phase 2b study will investigate the efficacy of REVTx-99 on viral load and patient-reported flu symptoms- - Top-line data anticipated in the second quarter of 2022 - SAN DIEGO, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (Revelation), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, announced today it has received approval from the Federal Agency for Medicines and Health Products (FAMHP) and the local Committee of Medical Ethics in Belgium to conduct a Phase 2b influenza viral challenge study. The Phase 2b, randomized, double-blind, influenza viral challenge study (RV

      9/28/21 9:00:00 AM ET
      $PAIC
      Business Services
      Finance
    • Revelation Biosciences, Inc., a Life Sciences Company Developing Therapeutics and Diagnostics for Respiratory Viral Infections, Including COVID-19, to Become Publicly Traded Through a Merger with Petra Acquisition, Inc.

      Revelation's lead product candidate REVTx-99 has potential, through innate immune system stimulation, to broadly prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2 including its variants, influenza A and B, parainfluenza, rhinovirus, and respiratory syncytial virus (RSV) Combined company expected to have a post-transaction pro forma total enterprise value of approximately $128 million Merger expected to close in Q4 2021, and combined company will be listed on NASDAQ under the ticker symbol "REVB" Revelation and Petra Acquisition will host a joint investor conference call and webcast to discuss the proposed transaction on August 30, 2021 at 4:30 p.m

      8/30/21 6:00:00 AM ET
      $PAIC
      Business Services
      Finance
    • PETRA ACQUISITION, INC. RECEIVES EXPECTED NASDAQ NOTIFICATION REGARDING DELAYED FORM 10-Q

      New York, NY, June 01, 2021 (GLOBE NEWSWIRE) -- Petra Acquisition, Inc. (NASDAQ:PAIC) (the "Company"), a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities, announced that on May 28, 2021, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") advising that because the Company failed to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2021 (the "Form 10-Q"), the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"). Nasdaq has inform

      6/1/21 4:30:00 PM ET
      $PAIC
      Business Services
      Finance

    $PAIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Feis Lawrence disposed of $7,465,890 worth of shares (731,950 units at $10.20)

      4 - Petra Acquisition Inc. (0001810560) (Issuer)

      1/11/22 3:59:54 PM ET
      $PAIC
      Business Services
      Finance
    • SEC Form 3: New insider Feis Lawrence claimed ownership of 746,491 shares

      3 - Petra Acquisition Inc. (0001810560) (Issuer)

      11/2/21 2:39:14 PM ET
      $PAIC
      Business Services
      Finance
    • SEC Form 4: Glazer Capital, Llc sold $6,597,824 worth of Common stock (654,546 units at $10.08)

      4 - Petra Acquisition Inc. (0001810560) (Issuer)

      9/23/21 4:21:06 PM ET
      $PAIC
      Business Services
      Finance

    $PAIC
    Financials

    Live finance-specific insights

    See more
    • Revelation Biosciences, Inc., a Life Sciences Company Developing Therapeutics and Diagnostics for Respiratory Viral Infections, Including COVID-19, to Become Publicly Traded Through a Merger with Petra Acquisition, Inc.

      Revelation's lead product candidate REVTx-99 has potential, through innate immune system stimulation, to broadly prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2 including its variants, influenza A and B, parainfluenza, rhinovirus, and respiratory syncytial virus (RSV) Combined company expected to have a post-transaction pro forma total enterprise value of approximately $128 million Merger expected to close in Q4 2021, and combined company will be listed on NASDAQ under the ticker symbol "REVB" Revelation and Petra Acquisition will host a joint investor conference call and webcast to discuss the proposed transaction on August 30, 2021 at 4:30 p.m

      8/30/21 6:00:00 AM ET
      $PAIC
      Business Services
      Finance

    $PAIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Petra Acquisition, Inc. (Amendment)

      SC 13G/A - Petra Acquisition Inc. (0001810560) (Subject)

      1/11/22 3:34:57 PM ET
      $PAIC
      Business Services
      Finance
    • SEC Form SC 13G/A filed by Petra Acquisition, Inc. (Amendment)

      SC 13G/A - Petra Acquisition Inc. (0001810560) (Subject)

      10/12/21 4:02:40 PM ET
      $PAIC
      Business Services
      Finance
    • SEC Form SC 13G/A filed by Petra Acquisition, Inc. (Amendment)

      SC 13G/A - Petra Acquisition Inc. (0001810560) (Subject)

      10/12/21 10:33:03 AM ET
      $PAIC
      Business Services
      Finance